Journal Mobile Options
Table of Contents
Vol. 110, No. 4, 2008
Issue release date: June 2008
Cardiology 2008;110:217–225
(DOI:10.1159/000112403)

Prognostic Value of Natriuretic Peptides in Chagas’ Disease: A 3-Year Follow-Up Investigation

Moreira M.V. · Heringer-Walther S. · Wessel N. · Moreira Ventura T. · Wang Y. · Schultheiss H.-P. · Walther T.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Chagas’ disease (CD) affects around 18 million people in Latin America. To determine the diagnostic and prognostic value of natriuretic peptides in patients with CD, we measured atrial (ANP) and brain natriuretic peptide (BNP), and compared the findings with other dilated cardiomyopathies (DCM). Methods: Blood samples were obtained from 111 CD patients, 62 patients with DCM due to other causes, and 43 gender- and age-matched healthy subjects. The CD and DCM patients were subdivided according to their NYHA classification. Natriuretic peptide concentrations were determined by immunoradiometric assays. Results: ANP and more pronounced BNP levels were increased in CD and DCM patients in relation to the NYHA class. Circulating BNP concentrations were higher in CD patients in NYHA classes I–II than in the corresponding DCM patients (p = 0.020). Importantly, ANP and BNP were already significantly elevated in CD patients without systolic ventricular dysfunction (p ≤ 0.001). In CD patients, both peptides were highly correlated with echocardiographic parameters (p < 10–14). Both ANP and BNP had comparable ability to predict death or the necessity for heart transplant (p < 0.0001). Conclusion: Natriuretic peptide levels can be used as a marker of asymptomatic CD without ventricular dysfunction and thus could be an ideal tool to identify these patients for early therapy.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Chagas’ disease – an epidemic that can no longer be ignored (editorial). Lancet 2006;368:619.
  2. Laranja FS, Dis E, Nobrega G, Miranda A: Chagas’ disease: a clinical, epidemiologic, and pathologic study. Circulation1956;14:1035–1060.
  3. Morris AS, Tanowitz HB, Wittner M, Bilezikian JP: Pathophysiological insights into the cardiomyopathy of Chagas’ disease. Circulation 1990;82:1900–1909.
  4. Bocchi EA: Situação atual das indicações e resultados do tratamento cirúrgico da insuficiência cardíaca. Arq Bras Cardiol 1994;63:523–530.
  5. Sakata Y, Yamamoto K, Masuyama T, Mano T, Nishikawa N, Kuzuya T, Miwa T, Hori M: Ventricular production of natriuretic peptides and ventricular structural remodelling in hypertensive heart failure. J Hypertens 2001;19:1905–1912.
  6. Chen HH, Burnett JC: Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep 2000;2:198–205.
  7. Walther T, Siems WE, Hauke D, Spillmann F, Dendorfer A, Krause W, Schultheiss HP, Tschope C: AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats. FASEB J 2002;16:1237–1241.
  8. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, Luchner A, McDonagh T, Mair J, Nieminen M, Francis G: Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003;24:1710–1718.
  9. Walther T, Stepan H, Faber R: Dual natriuretic response to volume load in the fetal circulation. Cardiovasc Res 2001;49:817–819.
  10. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1057–1059.
  11. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek S, Packer R: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392–2397.
  12. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126–1130.
  13. Clerico A, Iervasi G, Pilo A: Turnover studies on cardiac natriuretic peptides: methodological, pathophysiological and therapeutical considerations. Curr Drug Metab 2000;1:85–105.
  14. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115–1140.
  15. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154–e235.
  16. Mathisen P, Hall C, Simonsen S: Comparative study of atrial peptides ANF (1–98) and ANF (99–126) as diagnostic markers of atrial distension in patients with cardiac disease. Scand J Clin Lab Invest 1993;53:41–49.
  17. Walther T, Heringer-Walther S, Wessel N, Schultheiss HP, Moreira Mda C: Brain natriuretic peptide as a predictor of cardiomyopathy in Chagas’ disease. Lancet 2003;361:1567.
  18. Heringer-Walther S, Moreira MCV, Wessel N, Saliba JL, Silva-Barra J, Pena JL, Becker S, Siems WE, Schultheiss HP, Walther T: Brain natriuretic peptide predicts survival in Chagas’ disease more effective than atrial natriuretic peptide. Heart 2005;91:385–387.
  19. Puyo AM, Scaglione J, Auger S, Cavallero S, Donoso AS, Dupuy HA, Fernandez BE: Atrial natriuretic factor as marker of myocardial compromise in Chagas’ disease. Regul Pept 2002;105:139–143.
  20. Ribeiro AL, dos Reis AM, Barros MV, de Sousa MR, Rocha AL, Perez AA, Pereira JB, Machado FS, Rocha MO: Brain natriuretic peptide and left ventricular dysfunction in Chagas’ disease. Lancet 2002;360:461–462.
  21. Mocelin AO, Issa VS, Bacal F, Guimaraes GV, Cunha E, Bocchi EA: The influence of aetiology on inflammatory and neurohumoral activation in patients with severe heart failure: a prospective study comparing Chagas’ heart disease and idiopathic dilated cardiomyopathy. Eur J Heart Fail 2005;7:869–873.
  22. Scaglione J, Puyo AM, Dupuy HA, Postan M, Fernandez BE: Behavior of atrial natriuretic factor in an experimental model of Trypanosoma cruzi infection in rats. J Parasitol 2001;87:923–926.
  23. Walther T, Klostermann K, Heringer-Walther S, Schultheiss HP, Tschope C, Stepan H: Fibrosis rather than blood pressure determines cardiac BNP expression in mice. Regul Pept 2003;116:95–100.
  24. Wei CM, Heublein DM, Perella MA: Natriuretic peptide system in human heart failure. Circulation 1993;88:1004–1009.
  25. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki M: Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 2000;97:4239–4244.
  26. Ogawa Y, Tamura N, Chusho H, Nakao K: Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. Can J Physiol Pharmacol 2001;79:723–729.
  27. Factor SM, Tanowitz H, Wittner M, Ventura MC: Interstitial connective tissue matrix alterations in acute murine Chagas’ disease. Clin Immunol Immunopathol 1993;68:147–152.
  28. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, Burnett JC Jr: Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002;91:1127–1134.
  29. Cho Y, Somer BG, Amatya A: Natriuretic peptides and their therapeutic potential. Heart Dis 1999;1:305–328.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50